 Citibank said it still expects the outcome of the Daubert evidence admissibility hearings into Zantac to be favourable to the defendants including GlaxoSmithKline and Sanofi after the initial proceedings. We anticipate investors expectations for liabilities to be meaningfully pared back pending the anticipated Daubert ruling, the US bank said in a note. 